137 related articles for article (PubMed ID: 28355452)
1. Low-Density Lipoprotein Measurement Discordance: When 2 Wrongs Lead to the Right Answer-Elevated Lipoprotein (a).
Intwala S; Stone NJ; Balady GJ
JAMA Cardiol; 2017 Jun; 2(6):697-698. PubMed ID: 28355452
[No Abstract] [Full Text] [Related]
2. The relationship between apolipoprotein B-100 and low-density lipoprotein cholesterol after treatment with an HMG CoA reductase inhibitor.
Levinson SS; Blevins RD; Smith MP; Rubinfire M; Maciejko JJ
Am J Clin Pathol; 1989 Oct; 92(4):479-83. PubMed ID: 2508466
[TBL] [Abstract][Full Text] [Related]
3. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
4. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
[TBL] [Abstract][Full Text] [Related]
5. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
[No Abstract] [Full Text] [Related]
6. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
Sniderman AD; Thanassoulis G
Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
[No Abstract] [Full Text] [Related]
7. Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a).
Süleymanlar G; Ozben T; Sapan M; Yìlmaz H; Yakupoglu G; Karpuzoglu T
Transplant Proc; 1994 Oct; 26(5):2637-8. PubMed ID: 7940822
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
[TBL] [Abstract][Full Text] [Related]
9. New guidelines in statin therapy.
Dinman S
Plast Surg Nurs; 2005; 25(2):109-10. PubMed ID: 15983503
[No Abstract] [Full Text] [Related]
10. [Update: clinical lipidology].
Parhofer KG
MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
[No Abstract] [Full Text] [Related]
11. HMG-CoA reductase inhibitors.
Grundy SM
J Intern Med; 1990 Sep; 228(3):201-5. PubMed ID: 2401870
[No Abstract] [Full Text] [Related]
12. Statins and almonds to lower lipoproteins (the STALL Study).
Ruisinger JF; Gibson CA; Backes JM; Smith BK; Sullivan DK; Moriarty PM; Kris-Etherton P
J Clin Lipidol; 2015; 9(1):58-64. PubMed ID: 25670361
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
[No Abstract] [Full Text] [Related]
14. Lipid parameters and cardiovascular events in patients taking statins.
Brook RD; Rubenfire M
JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
[No Abstract] [Full Text] [Related]
15. Lipid parameters and cardiovascular events in patients taking statins.
Martin SS; Jones SR
JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
[No Abstract] [Full Text] [Related]
16. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of non-high-density lipoprotein cholesterol and its application in pediatrics].
Chen LH; Shi XF; Liang L
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):436-8. PubMed ID: 24120061
[No Abstract] [Full Text] [Related]
18. Apolipoprotein B level in patients with type 2 diabetes who achieved goal of low density lipoprotein cholesterol and non-high density lipoprotein cholesterol.
Sathavarodom N; Boonyavarakul A
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S166-72. PubMed ID: 21280530
[TBL] [Abstract][Full Text] [Related]
19. Statins and aortic stenosis in the context of ratio of low- to high-density lipoprotein cholesterol.
Yilmaz MB
J Am Coll Cardiol; 2007 Jul; 50(3):289-90; author reply 290. PubMed ID: 17631225
[No Abstract] [Full Text] [Related]
20. Achieving lipid goals. A study of outcomes in an NP Clinic.
Adkins J; Stanley M
Adv Nurse Pract; 2007 Jun; 15(6):61-2, 64. PubMed ID: 19999011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
